Companies such as Xintong Pharmaceuticals, Human Capital Co., Ltd., and Wallei Intelligence have accepted IPOs on the Shanghai Stock Exchange

The Zhitong Finance App learned that Xi'an Xintong Pharmaceutical Research Co., Ltd., Hangzhou Wolei Intelligent Technology Co., Ltd., Jiangsu Gaokai Precision Fluid Technology Co., Ltd., Deep Blue Ocean Technology Co., Ltd., and Suzhou Tongxin Medical Technology Co., Ltd. have accepted IPOs on the Shanghai Stock Exchange.

According to the prospectus, Xintong Pharmaceutical is a high-tech enterprise focusing on drug development for more than 20 years. It focuses on drug development in major liver diseases such as hepatitis B, fatty hepatitis related to metabolic dysfunction, and liver cancer. It is committed to developing innovative drugs with independent intellectual property rights, safe and effective, and clinical value-oriented, striving to fill unmet clinical needs in the field of liver disease. It has now rapidly developed into a competitive new drug development enterprise for liver disease. As of the date of signing of the prospectus, the issuer has 8 core products for the treatment of liver disease, including: 1 innovative drug product, prefovir mesylate tablets, has been approved for marketing, 2 products MB07133 for injection and hepnofovir fumarate tablets are in the registered clinical trial stage with seamless phase II/III connections, 1 product XTYW001 has completed phase IA clinical trials, 1 product XTYW007 has submitted an IND application, and 3 liver disease products are under pre-clinical development.

Renben Co., Ltd. is mainly engaged in R&D, production and sales of bearings and related products. It is the largest and most comprehensive bearing manufacturing group in China. The company's business scope covers more than 70 countries and regions around the world. It has established nine major production bases at home and abroad, with a total of nearly 20,000 employees. It has R&D and manufacturing capabilities for the entire industry chain from bearing materials and bearing components to finished bearing products. The company's bearing products have more than 50,000 types and specifications, and are widely used in many important fields of the national economy, such as the automobile industry, light machinery, heavy machinery and major equipment. Since 2013, production and sales have ranked first in the domestic industry for 12 consecutive years. With comprehensive technology, product quality and business scale rapidly approaching the top eight international companies in the bearing industry, the company has now become the only Chinese enterprise in the top ten in the global bearing industry.

Wallei Intelligence is mainly engaged in R&D, production, sales and service of intelligent testing equipment and intelligent manufacturing production lines, providing overall intelligent manufacturing solutions for emerging industries such as new energy vehicles and power semiconductors. It is a national key “little giant” enterprise in this field. The company is a leading domestic provider of intelligent inspection and intelligent manufacturing solutions covering the entire cycle of automotive electronic product R&D and verification, online inspection and automated manufacturing.

Gaokai Technology specializes in R&D, production and sales of key control components and related equipment in the field of precision fluid control. Through continuous and unremitting efforts, the company's product layout continues to improve. Currently, the company's products focus on flow control series, dispensing and packaging series, and precision gluing series, and extend to more types of precision fluid control components and related equipment such as semiconductor vacuum system components, which are widely used in intelligent manufacturing fields such as semiconductors, consumer electronics, automotive electronics, and new energy.

Deep Blue's main business is R&D, production, sales and service of products such as cable-controlled underwater robots, autonomous underwater vehicles, underwater gliders, automatic cross-section buoys, and underwater propulsion robots. It anchors the “deep sea technology” field, and provides products and professional solutions for marine safety, marine engineering, emergency rescue, water conservancy and hydropower, marine research, and marine cultural tourism. The company is a pioneer in the development of a full spectrum of products in the field of underwater robots in China. After more than ten years of continuous R&D and innovation accumulation, the company has mastered 15 core technologies in four categories, continuing research on underwater robot system technology, underwater robot control navigation and communication technology, and advanced manufacturing technology for underwater robots. Relying on the self-developed core technology system described above, the issuer has built a complete product line covering cable-controlled underwater robots, autonomous underwater robots, and underwater booster robots, making it one of the few enterprises in the industry with independent R&D and large-scale production capabilities for a full range of underwater robots.

Tongxin Medical is a global innovative medical device company that uses breakthrough new technologies and solutions to advance the treatment and market development of advanced heart failure. In the Chinese market, the company's first implantable full-maglev left ventricular assist system, CH-VAD, has been approved for marketing by the State Drug Administration, becoming the first fully magnetic levitation implantable artificial heart in China. Its iterative version, CH-VADPlus, is also currently in the registration stage and is expected to be approved for sale in China in early 2026; in the US market, Briovad, a new-generation implantable fully maglev left ventricular assist system developed by the US FDA has been approved for clinical trials. Devices; In the European market, the company has officially submitted an application for pre-marketing clinical study BrioLife, which is expected to commence in the first half of 2026.